Swiss eye care company Alcon has raised its profit outlook for 2026, citing a smaller-than-expected hit from US tariffs and a refund from US authorities that is expected to arrive in the third quarter. The company now forecasts core earnings per share (EPS) growth of 12% to 15%, up from its previous range of 10% to 13%.
Alcon kept its sales growth guidance unchanged at 5% to 7%, but it now expects to convert more of that revenue into profit. The company also lifted its core operating margin expansion forecast to 90 to 190 basis points, from an earlier 70 to 170 basis points. A basis point is one-hundredth of a percentage point.
Why the outlook improved
The main driver behind the upgrade is a reduction in the expected impact of US tariffs on Alcon's business. Tariffs are taxes on imported goods, and companies that manufacture overseas and sell into the US often bear some of the cost. Alcon had previously factored in a larger tariff burden for 2026, but that estimate has now shrunk, giving the company more room to grow profits.
In addition, Alcon expects to receive a refund from US authorities in the third quarter. The company did not specify the amount or the reason for the refund, but such payments can occur when a company overpays duties or when trade rulings change. This one-time boost will help lift earnings in the second half of the year.
Alcon is a major player in the eye care market, selling surgical equipment and contact lenses under brands like Dailies and Air Optix. The company competes with Johnson & Johnson and Bausch + Lomb in the contact lens space, and with Carl Zeiss Meditec in surgical devices. Because its products are sold globally, trade policy and currency swings can have a noticeable effect on its financial results.
What it means for investors
For everyday investors, the key takeaway is that Alcon is becoming more profitable on the same level of sales. That is a sign of improving operational efficiency and a lighter cost burden from tariffs. The company's ability to raise its margin outlook while keeping sales guidance steady suggests management is confident about cost control and pricing power.
However, investors should note that the improved EPS growth is partly due to a one-time refund, which may not repeat in future years. Core EPS growth of 12% to 15% is still solid for a large-cap healthcare company, but the underlying, recurring growth rate may be somewhat lower once the refund is stripped out.
Alcon's update comes at a time when many multinational companies are grappling with trade uncertainty. Tariffs have been a recurring theme in corporate earnings calls, and companies that can mitigate their impact—through supply chain shifts or pricing—tend to be rewarded by investors. Alcon's smaller tariff hit is a positive signal, but it also highlights how exposed global firms are to trade policy changes.
Looking ahead, investors will likely watch Alcon's third-quarter results to see the refund materialize and to gauge whether the company can sustain its margin expansion. The company's next earnings report will also show whether the 5% to 7% sales growth target remains on track, especially in key markets like the US and Asia.
For those who own Alcon shares, the raised outlook is a welcome development. For those considering an investment, it's worth remembering that profit forecasts can change quickly, especially when trade policy is involved. As always, it's wise to look at the broader picture—including the company's competitive position and long-term growth drivers—rather than reacting to a single guidance update.
Alcon's announcement is part of a broader trend of companies adjusting their 2026 outlooks as they get more clarity on tariffs and other costs. Similar moves have been seen across sectors, from CEZ lifting its profit outlook to Rapid7 raising its 2026 guidance. Each company faces its own set of challenges, but the common thread is that management teams are becoming more confident about the year ahead.
